GlassScriptPhysician profile
Nida Hameed
NPI 1881866218
$3,650.57
in general payments reported to CMS, 2019-2025
21 companies · $857 in 2025
The $857 reported for 2025 was more than what 77% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $326 · 2020: $57.07 · 2021: $46.70 · 2022: $697 · 2023: $971 · 2024: $695 · 2025: $857.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,420 · Education: $103.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,419.97 |
| Education | $103.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $675.66 | 2019-2025 | Veklury |
| Viiv Healthcare Company | $654.58 | 2021-2025 | Dovato, Cabenuva, Rukobia |
| Merck Sharp & Dohme LLC | $532.35 | 2019-2025 | Zerbaxa, Dificid, Pifeltro |
| Paratek Pharmaceuticals, INC. | $323.96 | 2022-2025 | Nuzyra |
| Insmed, INC. | $219.10 | 2023-2025 | Arikayce |
| Abbvie INC. | $190.70 | 2021-2025 | |
| Janssen Biotech, INC. | $163.83 | 2022-2023 | Symtuza |
| Tetraphase Pharmaceuticals, INC. | $135.66 | 2019 | |
| Melinta Therapeutics, LLC | $132.67 | 2022-2025 | Kimyrsa, Rezzayo, Orbactiv |
| Cumberland Pharmaceuticals, INC. | $128.17 | 2023-2025 | Vibativ |
| Boehringer Ingelheim Pharmaceuticals, INC. | $104.57 | 2023 | Jardiance |
| La Jolla Pharmaceutical Company | $77.06 | 2023-2025 | Xerava, Zevtera |
| Shionogi INC | $75.13 | 2022 | |
| Mayne Pharma Commercial LLC | $52.55 | 2020-2022 | |
| Allergan, INC. | $42.11 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Products, LP | $31.49 | 2022 | |
| Glaxosmithkline, LLC. | $25.92 | 2025 | Blujepa |
| Organogenesis INC. | $24.87 | 2025 | Simplimax |
| Aimmune Therapeutics, INC. | $23.28 | 2024 | |
| Ferring Pharmaceuticals INC. | $18.69 | 2025 | Rebyota |
| Cormedix INC. | $18.22 | 2025 | Defencath |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nida Hameed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.